Skip to Content
  • Revenues ($M)$135,962
  • Revenue Percent Change13.7%
  • Profits ($M)$-135
  • Profits Percent Change-148.8%
  • Assets ($M)$27,736
  • Employees17,000
  • Market Value — as of March 31, 2016 ($M)$19,511
  • Previous Rank16
  • Morning Consult Brand Index
    D

AmerisourceBergen is the second-largest distributor of pharmaceuticals in the U.S. As such, it’s subject to many of the same forces affecting McKesson, its top competitor. Generic drug price deflation and fewer expected generic-drug launches will put pressure on overall industry profits this year and next. AmerisourceBergen has been working to counter those effects by entering new markets through strategic acquisitions. This includes getting into animal health distribution with MWI Veterinary Supply, compounding with PharMEDium, and clinical trial logistics with World Courier. AmerisourceBergen also could face a windfall of new revenue in coming years after its partner Walgreens absorbs Rite Aid and its more than 4,500 pharmacists.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Steven H. Collis
Sector
Health Care
Industry
Wholesalers: Health Care
HQ Location
Chesterbrook, PA
Websitehttp://www.amerisourcebergen.com
Years on Fortune 500 List22
Employees17,000
Figures are for fiscal year ended Sept. 30, 2015.

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$135,96213.7%
Profits ($M)$-135-148.8%
Assets ($M)$27,736-
Total Stockholder Equity ($M)$634-
Market Value — as of March 31, 2016 ($M)$19,511-

Profit Ratios

Profit as % of Revenues-0.1%
Profits as % of Assets-0.5%
Profits as % of Stockholder Equity-21.3%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)-0.62
EPS % Change (from 2014)-153%
EPS % Change (5 year annual rate)-
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2015)16.4%
Total Return to Investors (5 year, annualized)26.6%
Total Return to Investors (10 year, annualized)19.1%